The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence

Abstract

Prostate cancer (PCa) induced death is the predominant cause of cancer-related death among men in 48 countries. After radical treatment, biochemical recurrence has become an important factor for prognosis. The early detection and diagnosis of recurrent lesions are very helpful in guiding treatment and improving the prognosis. PET/CT is a promising method for early detection of lesions in patients with biochemical recurrence of prostate cancer. This article reviews the progress of the research on PET/CT in the PCa biochemical recurrence and aims to introduce new technologies and provide more direction for future research.

Background

Prostate cancer (PCa), the fifth reason of cancer-related death among male, is also the second most commonly diagnosed cancer (1). In 2020 1.4 million cases were newly diagnosed and 375,000 deaths were identified around the world (2). With the general promotion of prostate-specific antigen (PSA) screening, the improvement of biopsy technology, as well as the optimization of treatment methods, both of the incidence and mortality rates of PCa have declined or stabilized in most countries in recent years. However, the incidence of advanced PCa has increased (2, 3). Prostate cancer is a malignant tumor with extremely heterogeneous clinical behavior and has biological behaviors ranging from inertia and organ limitation to rapid invasion and easy metastasis (4). It is diagnosed mainly through digital rectal examination (DRE) and PSA testing. Once a preliminary diagnosis is made, a needle biopsy guided by a rectal ultrasound (TRUS) is performed (5). After an initial treatment via radical prostatectomy (RP) or local radiotherapy (RT), almost half of patients develop biochemical recurrence (BCR) and an increase in PSA. After a potential remedial treatment option, androgen deprivation therapy (ADT) is usually used for the patient. After the ADT, prostate-specific antigens begin to rise again in 2-8 years, and metastatic castration-resistant PCa can develop (6). Studies have shown that salvage RT (SRT) after early RP provides a cure for increased PSA in patients after RP (7–9), and therefore, early detection of BCR and lesion metastasis and accurate restaging guidance for the treatment of recurrent PCa is very important. Both of CT and MRI are structural imaging techniques and are of limited sensitivity and specificity for detecting a minimal metastatic lesion, which leads to a lower diagnostic rate for common imaging techniques in asymptomatic patients (10). The molecular imaging PET/CT is believed to be superior to BCR detection.

PET/CT Imaging Agent for BCR PCa

BCR is generally defined by elevated PSA values (more than 0.2 ng/ml) in consecutively two tests after RP (11, 12). For patients receiving radiation therapy, biochemical failure is defined as the end of radiotherapy with the lowest PSA increase in the last 6 weeks being ≥ 2 ng/mL (13). Over the past decade, a variety of PET probes have achieved good results in detecting recurrent lesions and disease staging in PCa patients. PET radiotracers that are used have developed rapidly and mainly include radiolabeled choline, prostate specific membrane antigen (PSMA) ligands,¹⁸F-fluciclovine, gastrin-releasing peptide receptor(GRPR), fibroblast activation protein inhibitors(FAPI) and so on (14–22) (Table 1)

PSMA is a highly overexpressed transmembrane glycoprotein detected in the majority of prostate cancer cells (23) and is located in the apical region of prostate cells (i.e., the prostate tube) (Figure 1). PSMA is expressed in peripheral epithelial cells (24), and high-grade PCa have higher PSMA expression, and PSMA expression in late and castration-resistant PCa is further increased (25). PSMA binds with high affinity to the folate hydrolase of the PC cells, allowing the PSMA to show its potential to recognize BCR sites (26), and becomes the target of PCa imaging and therapy. PSMA-PET exhibits good early detection and localization of PCa recurrence lesions and identification of BCR lymph node metastasis after RP (27, 28). (Table 2) And ⁶⁸Ga-PSMA-11 is the first FDA-approved radiotracer for PCa-specific PET/CT imaging (29, 30) (Table 2)

Figure 1

Choline radiopharmaceuticals were used for prostate cancer earlier, and often labeled with ¹¹C and ¹⁸F, which can be used for the detection of recurrent lesions and the detection of early recurrence in patients with a history of BCR PCa (31, 32). ¹⁸F-fluciclovine is a synthetic amino acid with good biodistribution and little urinary disturbance, is often used for restaging of BCR patients (33). Gastrin-releasing peptide receptor antagonist (RM2) binds to GRPR on PCa cells, complementary to PSMA-targeted imaging (15, 34). Fibroblast activation protein (FAP) is highly expressed in a variety of epithelial cancers, and FAP inhibitor (FAPI) PET/CT has been used for various tumor imaging. Research has confirmed the uptake of ⁶⁸Ga-FAPI-04 in PCa tissue was higher than that in normal prostate tissue, and FAP expression was increased after ADT, which has potential when the detection of lesions is limited after ADT (16, 21, 35).

Recurrent Lesions Detection and Localization

Patients with a large number of RPs have an elevated PSA, and early detection and localization of anatomical sites of recurrence are critical to guide subsequent treatment. PET/CT was believed to be better than a morphological-based standard imaging mode (CWU) (36). An analysis of prostate cancer in Asian populations showed that standard imaging was not sensitive to recurrent PCa, and none of the bone lesions detected by PET was detected by CWU (37). Choline-PET is the most widely studied method, and although it has excellent specificity (38), its sensitivity is low, especially when PSA levels are low (39). A prospective study showed a PSMA-PET/CT detection rate of 66%, which is remarkably higher than the ¹⁸F-choline PET/CT detection rate of 32% (40). ⁶⁸Ga-PSMA PET showed an obviously higher detection rate and a higher general impact on the clinical management than ¹⁸F-fluoromethylcholine (41, 42). ¹⁸F-fluciclovine has excellent detection rates for low, medium and high PSA levels (43, 44), and the test results are significantly better than those obtained with ¹¹C-choline (38, 45). A meta-analysis showed that in BCR patients, the combined detection rates of ¹⁸F-labeled choline, fluciclovir, and PSMA were 66%, 74%, and 83%, respectively (38). The study by Hoffmann et al. compared the detection rates of ¹⁸F-PSMA and ⁶⁸Ga-PSMA PET, and the results showed that the detection rates of the two tracers were similar, 87.5% (112/128) and 88.9% (121/136), respectively (46). A recent study showed, ⁶⁸Ga-P16-093, a small molecule PSMA ligand, detected 71% of lesions in BCR patients (47) (Table 3)

Previous studies have shown that PSMA PET has a higher detection rate than other tracers, and some researchers have found that when PSMA expression is low or PSMA negative tumor area ≥ 50%, PSMA-PET results are negative, although PSA levels are very high (56). When PSMA expression is low, Dietlein et al. found 5 ⁸⁹Zr-PSMA-DFO PET-positive lesions in 14 PSMA-PET-negative patients.⁸⁹Zr-PSMA-DFO PET becomes a good supplement because its half-life is long enough to allow the process of ligand internalization to proceed sufficiently to make the lesions visible (22, 56, 57). Targeting gastrin-releasing peptide receptor (GRPR) is thought to complement PSMA-negative prostate cancer (PCa) patients (58), and it is helpful for the localization of recurrent lesions in ¹⁸FECH PET/CT-negative patients (59).Another study showed that the detection rate of ¹⁸F-FDG PET/CT in PSMA-PET negative patients was 16.7%, and patients with PSA ≥2.3 ng/mL and high Gleason score were more likely to benefit from FDG PET (60).

Factors Affecting the Detection Rate

Many studies (41, 61–65) have indicated that PSMA, choline, fluciclovine PET/CT positive results possibly are significantly correlated with increased PSA levels (37). For patients with BCR, the positive rate of the PET/CT scan varies based on the clinical stage of the BCR, PSA levels as well as PSA doubling time during the scan are correlated with positive results (27, 66). A study showed that the detection rates of ¹⁸F-labeled choline, fluciclovine, and PSMA were 35, 23, and 58% for a PSA level less than 0.5 ng/ml;80, 92, and 94% for a PSA level more than 2.0 ng/ml (38). The rate of increase grows with a rise in the serum PSA levels before the PET (27, 67, 68). There are studies that shown that when the PSA levels higher than 0.2 ng/ml while the PSA velocity ≥ 1 ng/ml/year, there will be a positive PSMA scan (69), and with higher PSA levels, the PSMA-PET shows better diagnostic performance (28).

It has been documented that androgen deprivation therapy experience in BCR patients is correlated with the positive rate of PSMA-PET scans (69), and there is evidence that PSMA is induced with low doses of ADT at lower PSA levels (≤0.3 ng/mL). Imaging may enhance the positive scan rate (70), but further research is needed. In addition, the time to inject the imaging agent is related to the contrast of the image. For BCR with low PSA levels, imaging 3 hours after injection is more advantageous in terms of lesion contrast (71), which may also have an effect on the positive scan rate. Scanning technology and timing also have an impact on the positive rate. Morawitz et al. (72) found that ⁶⁸Ga-PSMA-11 PET/CT scanning in the late abdominal and pelvic stage after emptying the bladder was helpful to detect missed local recurrence lesions. Uprimny et al. (73) improved the detection rate of lesions by using furosemide before scanning.

PET Imaging for BCR of Low PSA Levels

Currently, salvage RT (SRT) is one valuable treatments for patients with PSA elevation after RP. Early diagnosis of BCR at low PSA levels has a major impact on patients’ follow-up treatment. EVU guidelines recommend that PSA levels greater than 0.2 ng/mL and results influence subsequent treatment decisions, imaging of biochemically recurrent PCa with PSMA-labeled PET/CT (74). A study in 2005 patients with BCR found that the detection rate of ⁶⁸Ga-PSMA-11 was 44.8% when the PSA was less than 0.25 ng/mL (49). A meta-analysis showed that the detection rates of ¹⁸F-Choline, ¹⁸F-Fluciclovine and ¹⁸F-PSMA PET/CT at PSA levels less than 0.5 ng/ml were 35%, 23%, and 58%, respectively (38). PEMA-PET is superior to other imaging methods at low PSA levels, as recommended by guidelines (Figure 2). ¹⁸F-fluciclovine PET is feasible for patients with PSA <1.0ng/ml. Filippi et al (54) found that the detection rate in 81 Italian patients was 66.7% when the PSA level was 0.2-0.57 ng/ml, and Wang et al. (75) in 46 patients with PSA level of 0.3-1.0ng/ml found the positive rate was about 33%, but it was not found positive cases in very low PSA (less than 0.3ng/ml) BCR patients. The value of ¹⁸F-fluciclovine PET in detecting lesions in BCR patients with very low PSA levels remains to be explored. A recent study found that at very low PSA (≤0.1ng/ml) levels, dynamic detection of ¹¹C-choline PET was helpful in detecting early recurrence in BCR PCa patients (32). This could be a valuable new direction.

Figure 2

Detection of Metastases in BCR Patients

Increased serum PSA levels are sensitive to in vitro markers of recurrent prostate cancer; however, it is still hard to differentiate local recurrence and regional or distant metastasis. Identifying metastatic disease can impact therapeutic schedule options and contributes to prognosis assessment (27). PSMA PET/CT is most commonly used to detect LN metastases and staging in BCR patients after RP, and its performance depends on the PSA levels as well as the volume of debris from metastatic cells (28). However, in small lymph nodes, this method performs well (76). Rauscher showed that ⁶⁸Ga-PSMA PET detected LNM (77.9%) in 68 histopathologically confirmed metastatic LN regions, whereas conventional imaging modality only detected 18 of 67 regions (26.9%) (77). Studies have shown that ¹⁸F-rhPSMA-7 and ¹⁸F-rhPSMA-7.3 PET have a detection rate of 81.3% for lymph node metastasis in BCR patients after RP, and their accuracy in evaluating lymph node metastasis is comparable to that of ¹⁸F-PSMA-11 ⁽78).PSMA-PET/CT has higher diagnostic accuracy for lymph node recurrence after RP, especially for small-volume metastases, ¹⁸ F-PSMA-1007 PET/CT can reliably detect malignant lymph nodes larger than 3 mm with a specificity of over 99% (79–81) (Figure 3)

Figure 3

Bone metastasis is one of the common metastasis methods of prostate cancer, and it is difficult to differentiate diagnosis by traditional imaging due to degenerative changes. Mingels et al. found in 177 BCR patients that the PPV of ¹⁸F-PSMA-1007 PET to identify bone lesions was 79%, which was lower than the positive rate of the overall and LN (82). A meta-analysis showed that the highest sensitivity of NaF-PET/CT in identifying bone metastases was 0.97, followed by PSMA PET, higher than choline, MRI and bone scintigraphy (83). A recent study found that ¹⁸F-NaF PET/CT detected 93.6% of bone metastases, and the interobserver agreement was very high, with stable and reproducible results (18).

PET/CT False Negatives and False Positives

For PSMA-PET, a small fraction (<10%) of PCa expressed low PSMA, which results in little or no uptake on PSMA-PET (79, 84). In these PSMA-negative patients, PSMA-PET is ineffective (36). In addition, metal artifacts low levels of PSMA uptake and bladder overflow are also possible elements of false negatives (85).Positive images need to be differentiated from normal tissue, benign lesions, and other non-PCa malignant lesions (25, 86–88). Reports have shown that in normal tissues, high or mild ⁶⁸ Ga-PSMA-11 uptake was observed in the renal cortex, duodenum, parotid gland, and submandibular salivary glands, spleen, lacrimal gland, and liver (89–92). In some benign tissues with high proliferation rate, just like heart valves, pleura, endometrial scars, and granulation tissue, endothelial cells also express PSMA (25, 93, 94). Abnormal accumulation of PSMA-PET were detected in lots of benign lesions, including sarcoidosis (86, 95), Paget’s disease (96), healing fractures (97, 98), hemangioma (99), schwannomas (100), adenoma (101), and so on. Malignant tumors other than PCa, such as renal cell carcinoma (102, 103) and hepatocellular carcinoma (104), also have high expression. In addition, ¹⁸F-fluorocholine imaging usually shows abnormal uptake in lymph nodes due to inflammatory changes (105).All of the above cause false positive results, so it is necessary to learn about the physiological uptake and normal distribution in order to reduce the false positive results in the diagnosis.

Conclusions

PSMA-PET has high accuracy in the detection of PCa BCR and the identification of metastasis, especially at low PSA levels. Its diagnostic potential is significantly better than that of choline and amino acid analogues, and this has a remarkable influence on managing patients in clinical. However, due to the expression and distribution characteristics of PSMA, it is unable to reliably recognize the PSMA-negative lesions, and other imaging methods need to be selected as supplements. According to the actual situation of patients, the combined use of complementary imaging agents to detect and locate BCR lesions is helpful for the early and effective detection and localization of recurrent lesions in BCR PCa patients, and is conducive to the selection of treatment options and the improvement of prognosis. Radiocomposites (such as ¹⁸F-NOTA-GRPR-PSMA, etc.) with the advantages of two or more imaging agents at the same time may become a research hotspot in the future.

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81960496), Yunnan Fundamental Research Projects (grant number 202101AT070050), the Project funded by China Postdoctoral Science Foundation (grant number 2019M653501), Scientific Research Fund of Yunnan Province Educational Department (grant number K13219357), Yunnan Provincial Science and Technology Agency/Kunming Medical University Joint Project [grant number #2019FE001(-087)], Kunming Medical University Graduate Innovation Fund (grant number 2021S070), and the Xingdianyingcai support plan.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1

  SiegelRLMillerKDFuchsHEJemalA. Cancer Statistics, 2021. Ca-a Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654

  • CrossRef
  • Google Scholar

• 2

  SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalAet al. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660

  • CrossRef
  • Google Scholar

• 3

  CulpMBSoerjomataramIEfstathiouJABrayFJemalA. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol (2020) 77(1):38–52. doi: 10.1016/j.eururo.2019.08.005

  • CrossRef
  • Google Scholar

• 4

  RodriguesDNButlerLMEstellesDLde BonoJS. Molecular Pathology and Prostate Cancer Therapeutics: From Biology to Bedside. J Pathol (2014) 232(2):178–84. doi: 10.1002/path.4272

  • CrossRef
  • Google Scholar

• 5

  MohlerJLAntonarakisESArmstrongAJD’AmicoAVDavisBJDorffTet al. Prostate Cancer, Version 2.2019, Nccn Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2019) 17(5):479–505. doi: 10.6004/jnccn.2019.0023

  • CrossRef
  • Google Scholar

• 6

  SchwarzenboeckSMRauscherIBluemelCFendlerWPRoweSPPomperMGet al. Psma Ligands for Pet Imaging of Prostate Cancer. J Nucl Med Off Publ Soc Nucl Med (2017) 58(10):1545–52. doi: 10.2967/jnumed.117.191031

  • CrossRef
  • Google Scholar

• 7

  PfisterDBollaMBrigantiACarrollPCozzariniCJoniauSet al. Early Salvage Radiotherapy Following Radical Prostatectomy. Eur Urol (2014) 65(6):1034–43. doi: 10.1016/j.eururo.2013.08.013

  • CrossRef
  • Google Scholar

• 8

  WiegelTLohmGBottkeDHochtSMillerKSiegmannAet al. Achieving an Undetectable Psa After Radiotherapy for Biochemical Progression After Radical Prostatectomy Is an Independent Predictor of Biochemical Outcome–Results of a Retrospective Study. Int J Radiat Oncol Biol Phys (2009) 73(4):1009–16. doi: 10.1016/j.ijrobp.2008.06.1922

  • CrossRef
  • Google Scholar

• 9

  SotoDEPassarelliMNDaignaultSSandlerHM. Concurrent Androgen Deprivation Therapy During Salvage Prostate Radiotherapy Improves Treatment Outcomes in High-Risk Patients. Int J Radiat Oncol Biol Phys (2012) 82(3):1227–32. doi: 10.1016/j.ijrobp.2010.08.030

  • CrossRef
  • Google Scholar

• 10

  RouviereOVitryTLyonnetD. Imaging of Prostate Cancer Local Recurrences: Why and How? Eur Radiol (2010) 20(5):1254–66. doi: 10.1007/s00330-009-1647-4

  • CrossRef
  • Google Scholar

• 11

  CooksonMSAusGBurnettALCanby-HaginoEDD’AmicoAVDmochowskiRRet al. Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes. J Urol (2007) 177(2):540–5. doi: 10.1016/j.juro.2006.10.097

  • CrossRef
  • Google Scholar

• 12

  CornfordPBellmuntJBollaMBriersEDe SantisMGrossTet al. Eau-Estro-Siog Guidelines on Prostate Cancer. Part Ii: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol (2017) 71(4):630–42. doi: 10.1016/j.eururo.2016.08.002

  • CrossRef
  • Google Scholar

• 13

  HofmanMSMurphyDGWilliamsSGNzenzaTHerschtalALourencoRAet al. A Prospective Randomized Multicentre Study of the Impact of Gallium-68 Prostate-Specific Membrane Antigen (Psma) Pet/Ct Imaging for Staging High-Risk Prostate Cancer Prior to Curative-Intent Surgery or Radiotherapy (Propsma Study): Clinical Trial Protocol. BJU Int (2018) 122(5):783–93. doi: 10.1111/bju.14374

  • CrossRef
  • Google Scholar

• 14

  BoustaniAMPucarDSapersteinL. Molecular Imaging of Prostate Cancer. Br J Radiol (2018) 91(1084):20170736. doi: 10.1259/bjr.20170736

  • CrossRef
  • Google Scholar

• 15

  BarattoLSongHDuanHHatamiNBagshawHPBuyyounouskiMet al. Psma- and Grpr-Targeted Pet: Results From 50 Patients With Biochemically Recurrent Prostate Cancer. J Nucl Med (2021) 62(11):1545–9. doi: 10.2967/jnumed.120.259630

  • CrossRef
  • Google Scholar

• 16

  KratochwilCFlechsigPLindnerTAbderrahimLAltmannAMierWet al. (68)Ga-Fapi Pet/Ct: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med (2019) 60(6):801–5. doi: 10.2967/jnumed.119.227967

  • CrossRef
  • Google Scholar

• 17

  MohsenBGiorgioTRasoulZSWernerLAliGRRezaDKet al. Application of C-11-Acetate Positron-Emission Tomography (Pet) Imaging in Prostate Cancer: Systematic Review and Meta-Analysis of the Literature. BJU Int (2013) 112(8):1062–72. doi: 10.1111/bju.12279

  • CrossRef
  • Google Scholar

• 18

  ZachoHDFonagerRFNielsenJBHaarmarkCHendelHWJohansenMBet al. Observer Agreement and Accuracy of (18)F-Sodium Fluoride Pet/Ct in the Diagnosis of Bone Metastases in Prostate Cancer. J Nucl Med (2020) 61(3):344–9. doi: 10.2967/jnumed.119.232686

  • CrossRef
  • Google Scholar

• 19

  BeattieBJSmith-JonesPMJhanwarYSSchöderHSchmidtleinCRMorrisMJet al. Pharmacokinetic Assessment of the Uptake of 16beta-18f-Fluoro-5alpha-Dihydrotestosterone (Fdht) in Prostate Tumors as Measured by Pet. J Nucl Med (2010) 51(2):183–92. doi: 10.2967/jnumed.109.066159

  • CrossRef
  • Google Scholar

• 20

  MüllerPJDietleinMKobeCHeidenreichADrzezgaA. Oligometastatic Disease in Biochemical Recurrence of Prostate Cancer: Prevalence on Psma Pet/Ct and Consecutive Metastasis-Directed Therapy - Experience at a Tertiary Referral Center. Nuklearmedizin (2022). doi: 10.1055/a-1697-8111

  • CrossRef
  • Google Scholar

• 21

  KeschCYirgaLDendlKHandkeADarrCKrafftUet al. High Fibroblast-Activation-Protein Expression in Castration-Resistant Prostate Cancer Supports the Use of Fapi-Molecular Theranostics. Eur J Nucl Med Mol Imaging (2021) 49(1):385–9. doi: 10.1007/s00259-021-05423-y

  • CrossRef
  • Google Scholar

• 22

  VázquezSMEndepolsHFischerTTawadrosSGHohbergMZimmermannsBet al. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-Specific Membrane Antigen for Pet Imaging in Prostate Cancer. Mol Imaging Biol (2022) 24(1):115–25. doi: 10.1007/s11307-021-01632-x

  • CrossRef
  • Google Scholar

• 23

  MannweilerSAmersdorferPTrajanoskiSTerrettJAKingDMehesG. Heterogeneity of Prostate-Specific Membrane Antigen (Psma) Expression in Prostate Carcinoma With Distant Metastasis. Pathol Oncol Res: POR (2009) 15(2):167–72. doi: 10.1007/s12253-008-9104-2

  • CrossRef
  • Google Scholar

• 24

  DeMarzoAMNelsonWGIsaacsWBEpsteinJI. Pathological and Molecular Aspects of Prostate Cancer. Lancet (London England) (2003) 361(9361):955–64. doi: 10.1016/s0140-6736(03)12779-1

  • CrossRef
  • Google Scholar

• 25

  BostwickDGPacelliABluteMRochePMurphyGP. Prostate Specific Membrane Antigen Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Study of 184 Cases. Cancer (1998) 82(11):2256–61. doi: 10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s

  • CrossRef
  • Google Scholar

• 26

  KaittanisCAndreouCHieronymusHMaoNFossCAEiberMet al. Prostate-Specific Membrane Antigen Cleavage of Vitamin B9 Stimulates Oncogenic Signaling Through Metabotropic Glutamate Receptors. J Exp Med (2018) 215(1):159–75. doi: 10.1084/jem.20171052

  • CrossRef
  • Google Scholar

• 27

  PereraMPapaNChristidisDWetherellDHofmanMSMurphyDGet al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. Eur Urol (2016) 70(6):926–37. doi: 10.1016/j.eururo.2016.06.021

  • CrossRef
  • Google Scholar

• 28

  AbufarajMGrubmullerBZeitlingerMKramerGSeitzCHaitelAet al. Prospective Evaluation of the Performance of [(68)Ga]Ga-Psma-11 Pet/Ct(Mri) for Lymph Node Staging in Patients Undergoing Superextended Salvage Lymph Node Dissection After Radical Prostatectomy. Eur J Nucl Med Mol Imaging (2019) 46(10):2169–77. doi: 10.1007/s00259-019-04361-0

  • CrossRef
  • Google Scholar

• 29

  MenaELindenbergLMChoykePL. New Targets for Pet Molecular Imaging of Prostate Cancer. Semin Nucl Med (2019) 49(4):326–36. doi: 10.1053/j.semnuclmed.2019.02.001

  • CrossRef
  • Google Scholar

• 30

  Fda. Approves First Psma-Targeted Pet Drug. J Nucl Med (2021) 62(2):11n.

  • Google Scholar

• 31

  HeidenreichABastianPJBellmuntJBollaMJoniauSvan der KwastTet al. Eau Guidelines on Prostate Cancer. Part Ii: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol (2014) 65(2):467–79. doi: 10.1016/j.eururo.2013.11.002

  • CrossRef
  • Google Scholar

• 32

  GargINathanMAPackardATKwonEDLarsonNBLoweVet al. (11)C-Choline Positron Emission Tomography/Computed Tomography for Detection of Disease Relapse in Patients With History of Biochemically Recurrent Prostate Cancer and Prostate-Specific Antigen ≤0.1 Ng/Ml. J Cancer Res Ther (2021) 17(2):358–65. doi: 10.4103/jcrt.JCRT_373_19

  • CrossRef
  • Google Scholar

• 33

  NappiAGFerrariCMammucciPRubiniDLavelliVSardaroAet al. [(18)F]Fluciclovine Pet/Ct Improves the Clinical Management of Early Recurrence Prostate Cancer Patients. Cancers (2022) 14(6):1461. doi: 10.3390/cancers14061461

  • CrossRef
  • Google Scholar

• 34

  TouijerKAMichaudLAlvarezHAVGopalanAKossatzSGonenMet al. Prospective Study of the Radiolabeled Grpr Antagonist Bay86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Eur Urol Oncol (2019) 2(2):166–73. doi: 10.1016/j.euo.2018.08.011

  • CrossRef
  • Google Scholar

• 35

  GündoğanCGüzelYCanCKaplanİKömekH. Fapi-04 Uptake in Healthy Tissues of Cancer Patients in (68)Ga-Fapi-04 Pet/Ct Imaging. Contrast Media Mol Imaging (2021) 2021:9750080. doi: 10.1155/2021/9750080

  • CrossRef
  • Google Scholar

• 36

  RaynKNElnabawiYAShethN. Clinical Implications of Pet/Ct in Prostate Cancer Management. Trans Androl Urol (2018) 7(5):844–54. doi: 10.21037/tau.2018.08.26

  • CrossRef
  • Google Scholar

• 37

  TanJSHGohCXYKohYSLiYTuanJKLChuaETet al. (68)Gallium-Labelled Psma-Pet/Ct as a Diagnostic and Clinical Decision-Making Tool in Asian Prostate Cancer Patients Following Prostatectomy. Cancer Biol Med (2019) 16(1):157–66. doi: 10.20892/j.issn.2095-3941.2018.0288

  • CrossRef
  • Google Scholar

• 38

  WangRShenGHuangMTianR. The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-Psma Pet/Ct in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis. Front Oncol (2021) 11:684629. doi: 10.3389/fonc.2021.684629

  • CrossRef
  • Google Scholar

• 39

  LiRRavizziniGCGorinMAMaurerTEiberMCooperbergMRet al. The Use of Pet/Ct in Prostate Cancer. Prostate Cancer Prostatic Dis (2018) 21(1):4–21. doi: 10.1038/s41391-017-0007-8

  • CrossRef
  • Google Scholar

• 40

  Afshar-OromiehAZechmannCMMalcherAEderMEisenhutMLinhartHGet al. Comparison of Pet Imaging With a (68)Ga-Labelled Psma Ligand and (18)F-Choline-Based Pet/Ct for the Diagnosis of Recurrent Prostate Cancer. Eur J Nucl Med Mol Imaging (2014) 41(1):11–20. doi: 10.1007/s00259-013-2525-5

  • CrossRef
  • Google Scholar

• 41

  MorigiJJStrickerPDvan LeeuwenPJTangRHoBNguyenQet al. Prospective Comparison of 18f-Fluoromethylcholine Versus 68ga-Psma Pet/Ct in Prostate Cancer Patients Who Have Rising Psa After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med (2015) 56(8):1185–90. doi: 10.2967/jnumed.115.160382

  • CrossRef
  • Google Scholar

• 42

  von EybenFEPicchioMvon EybenRRheeHBaumanG. (68)Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-Analysis. Eur Urol Focus (2018) 4(5):686–93. doi: 10.1016/j.euf.2016.11.002

  • CrossRef
  • Google Scholar

• 43

  BulbulJEGrybowskiDLovrecPSolankiAAGabrielMSWagnerRHet al. Positivity Rate of [(18)F]Fluciclovine Pet/Ct in Patients With Suspected Prostate Cancer Recurrence at Psa Levels Below 1 Ng/Ml. Mol Imaging Biol (2022) 24(1):42–9. doi: 10.1007/s11307-021-01644-7

  • CrossRef
  • Google Scholar

• 44

  GarzaDKandathilAXiYSubramaniamRM. 18f-Fluciclovine Pet/Ct Detection of Biochemical Recurrent Prostate Cancer in Patients With Psa Levels <2.00 Ng/Ml. Nucl Med Commun (2021) 42(8):907–13. doi: 10.1097/mnm.0000000000001412

  • CrossRef
  • Google Scholar

• 45

  NanniCSchiavinaRBrunocillaEBoschiSBorghesiMZanoniLet al. 18f-Fluciclovine Pet/Ct for the Detection of Prostate Cancer Relapse: A Comparison to 11c-Choline Pet/Ct. Clin Nucl Med (2015) 40(8):e386–91. doi: 10.1097/rlu.0000000000000849

  • CrossRef
  • Google Scholar

• 46

  HoffmannMAvon EybenFEFischerNRosarFMüller-HübenthalJBuchholzHGet al. Comparison of [(18)F]Psma-1007 With [(68)Ga]Ga-Psma-11 Pet/Ct in Restaging of Prostate Cancer Patients With Psa Relapse. Cancers (2022) 14(6):1479. doi: 10.3390/cancers14061479

  • CrossRef
  • Google Scholar

• 47

  LeeHScheuermannJSYoungAJDootRKDaube-WitherspoonMESchubertEKet al. Preliminary Evaluation of (68)Ga-P16-093, A Pet Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Mol Imaging Biol (2022). doi: 10.1007/s11307-022-01720-6

  • CrossRef
  • Google Scholar

• 48

  De ManKPironSVan LaekenNDelrueLFonteyneVLumenNet al. Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging: 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management. Mol Imaging Biol. (2022). doi: 10.1007/s11307-022-01724-2

  • CrossRef
  • Google Scholar

• 49

  Abghari-GerstMArmstrongWRNguyenKCalaisJCzerninJLinDet al. A Comprehensive Assessment of (68)Ga-Psma-11 Pet in Biochemically Recurrent Prostate Cancer: Results From a Prospective Multicenter Study on 2,005 Patients. J Nucl Med (2022) 63(4):567–72. doi: 10.2967/jnumed.121.262412

  • CrossRef
  • Google Scholar

• 50

  CeciFRoveraGIorioGCGuarneriAChiofaloVet al. Event-Free Survival After 68 Ga-PSMA-11 PET/CT in Recurrent Hormone-Sensitive Prostate Cancer (HSPC) Patients Eligible for Salvage Therapy. Eur J Nucl Med Mol Imaging (2022). doi: 10.1007/s00259-022-05741-9

  • CrossRef
  • Google Scholar

• 51

  MenaERoweSPShihJHLindenbergLTurkbeyBFourquetAet al. Predictors of 18F-DCFPyL-PET/CT Positivity in Patients With Biochemical Recurrence of Prostate Cancer After Local Therapy. J Nucl Med. (2021). doi: 10.2967/jnumed.121.262347

  • CrossRef
  • Google Scholar

• 52

  ZhouXJiangXLiuLWangXLiCYaoYet al. Evaluation of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy. Transl Oncol (2022) 15(1):101292. doi: 10.1016/j.tranon.2021.101292

  • CrossRef
  • Google Scholar

• 53

  ChristensenMTJochumsenMRKlingenbergSSørensenKDBorreMBoucheloucheKet al. Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT. Diagnostics (Basel) (2022) 12(1):195. doi: 10.3390/diagnostics12010195

  • CrossRef
  • Google Scholar

• 54

  FilippiLBagniOCrisafulliCCerioIBrunottiGChiaravallotiAet al. Detection Rate and Clinical Impact of Pet/Ct With (18)F-Facbc in Patients With Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study. Biomedicines (2022) 10(1):177. doi: 10.3390/biomedicines10010177

  • CrossRef
  • Google Scholar

• 55

  ZattoniFArtioliPBureiMChiaravallotiAChierichettiFDonnerDet al. Detection Rate of 18F-Choline Positron Emission Tomography/computed Tomography in Patients With Non-Metastatic Hormone Sensitive and Castrate Resistant Prostate Cancer. Q J Nucl Med Mol Imaging (2021). doi: 10.23736/S1824-4785.21.03366-5

  • CrossRef
  • Google Scholar

• 56

  FerraroDARüschoffJHMuehlematterUJKranzbühlerBMüllerJMesserliMet al. Immunohistochemical Psma Expression Patterns of Primary Prostate Cancer Tissue Are Associated With the Detection Rate of Biochemical Recurrence With (68)Ga-Psma-11-Pet. Theranostics (2020) 10(14):6082–94. doi: 10.7150/thno.44584

  • CrossRef
  • Google Scholar

• 57

  DietleinFKobeCVázquezSMFischerTEndepolsHHohbergMet al. An (89)Zr-Labeled Psma Tracer for Pet/Ct Imaging of Prostate Cancer Patients. J Nucl Med (2022) 63(4):573–83. doi: 10.2967/jnumed.121.262290

  • CrossRef
  • Google Scholar

• 58

  YeSLiHHuKLiLZhongJYanQet al. Radiosynthesis and Biological Evaluation of 18f-Labeled Bispecific Heterodimer Targeted Dual Gastrin-Releasing Peptide Receptor and Prostate-Specific Membrane Antigen for Prostate Cancer Imaging. Nucl Med Commun (2022) 43(3):323–31. doi: 10.1097/mnm.0000000000001520

  • CrossRef
  • Google Scholar

• 59

  WieserGPoppIChristian RischkeHDrendelVGrosuALBartholomäMet al. Diagnosis of Recurrent Prostate Cancer With Pet/Ct Imaging Using the Gastrin-Releasing Peptide Receptor Antagonist (68)Ga-Rm2: Preliminary Results in Patients With Negative or Inconclusive [(18)F]Fluoroethylcholine-Pet/Ct. Eur J Nucl Med Mol Imaging (2017) 44(9):1463–72. doi: 10.1007/s00259-017-3702-8

  • CrossRef
  • Google Scholar

• 60

  ChenRWangYShiYZhuYXuLHuangGet al. Diagnostic Value of (18)F-Fdg Pet/Ct in Patients With Biochemical Recurrent Prostate Cancer and Negative (68)Ga-Psma Pet/Ct. Eur J Nucl Med Mol Imaging (2021) 48(9):2970–7. doi: 10.1007/s00259-021-05221-6

  • CrossRef
  • Google Scholar

• 61

  EiberMMaurerTSouvatzoglouMBeerAJRuffaniAHallerBet al. Evaluation of Hybrid (6)(8)Ga-Psma Ligand Pet/Ct in 248 Patients With Biochemical Recurrence After Radical Prostatectomy. J Nucl Med (2015) 56(5):668–74. doi: 10.2967/jnumed.115.154153

  • CrossRef
  • Google Scholar

• 62

  Afshar-OromiehAAvtziEGieselFLHolland-LetzTLinhartHGEderMet al. The Diagnostic Value of Pet/Ct Imaging With the (68)Ga-Labelled Psma Ligand Hbed-Cc in the Diagnosis of Recurrent Prostate Cancer. Eur J Nucl Med Mol Imaging (2015) 42(2):197–209. doi: 10.1007/s00259-014-2949-6

  • CrossRef
  • Google Scholar

• 63

  HofmanMSHicksRJMaurerTEiberM. Prostate-Specific Membrane Antigen Pet: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics Rev Publ Radiol Soc North Am Inc (2018) 38(1):200–17. doi: 10.1148/rg.2018170108

  • CrossRef
  • Google Scholar

• 64

  VerburgFAPfisterDHeidenreichAVoggADrudeNIVooSet al. Extent of Disease in Recurrent Prostate Cancer Determined by [(68)Ga]Psma-Hbed-Cc Pet/Ct in Relation to Psa Levels, Psa Doubling Time and Gleason Score. Eur J Nucl Med Mol Imaging (2016) 43(3):397–403. doi: 10.1007/s00259-015-3240-1

  • CrossRef
  • Google Scholar

• 65

  CeciFUprimnyCNilicaBGeraldoLKendlerDKroissAet al. (68)Ga-Psma Pet/Ct for Restaging Recurrent Prostate Cancer: Which Factors Are Associated With Pet/Ct Detection Rate? Eur J Nucl Med Mol Imaging (2015) 42(8):1284–94. doi: 10.1007/s00259-015-3078-6

  • CrossRef
  • Google Scholar

• 66

  CeciFCastellucciPGrazianiTFarolfiAFontiCLodiFet al. (68)Ga-Psma-11 Pet/Ct in Recurrent Prostate Cancer: Efficacy in Different Clinical Stages of Psa Failure After Radical Therapy. Eur J Nucl Med Mol Imaging (2019) 46(1):31–9. doi: 10.1007/s00259-018-4189-7

  • CrossRef
  • Google Scholar

• 67

  EissaAElsherbinyACoelhoRFRassweilerJDavisJWPorpigliaFet al. The Role of 68ga-Psma Pet/Ct Scan in Biochemical Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review of the Literature. Minerva Urol Nefrol J Urol Nephrol (2018) 70(5):462–78. doi: 10.23736/s0393-2249.18.03081-3

  • CrossRef
  • Google Scholar

• 68

  YilmazUKomekHCanCAltindagS. The Role of [(68)Ga]Psma I&T in Biochemical Recurrence After Radical Prostatectomy: Detection Rate and the Correlation Between the Level of Psa, Gleason Score, and the Suvmax. Ann Nucl Med (2019) 33(8):545–53. doi: 10.1007/s12149-019-01360-x

  • CrossRef
  • Google Scholar

• 69

  AydinAMHaberalBArtykovMBilenCYYaziciS. Clinicopathological Predictors of Positive (68)Ga-Psma-11 Pet/Ct in Psa-Only Recurrence of Localized Prostate Cancer Following Definitive Therapy. Ann Nucl Med (2019) 33(5):326–32. doi: 10.1007/s12149-019-01340-1

  • CrossRef
  • Google Scholar

• 70

  LeitsmannCThelenPSchmidMMellerJSahlmannCOMellerBet al. Enhancing Psma-Uptake With Androgen Deprivation Therapy - a New Way to Detect Prostate Cancer Metastases? Int Braz J Urol (2019) 45(3):459–67. doi: 10.1590/s1677-5538.Ibju.2018.0305

  • CrossRef
  • Google Scholar

• 71

  HohbergMKobeCTagerPHammesJSchmidtMDietleinFet al. Combined Early and Late [(68)Ga]Psma-Hbed-Cc Pet Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer With Low Psa Levels. Mol Imaging Biol :MIB (2019) 21(3):558–66. doi: 10.1007/s11307-018-1263-2

  • CrossRef
  • Google Scholar

• 72

  MorawitzJKirchnerJHertelendyJLobergCSchimmöllerLDabirMet al. Is There a Diagnostic Benefit of Late-Phase Abdomino-Pelvic Pet/Ct After Urination as Part of Whole-Body (68) Ga-Psma-11 Pet/Ct for Restaging Patients With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy? EJNMMI Res (2022) 12(1):12. doi: 10.1186/s13550-022-00885-z

  • CrossRef
  • Google Scholar

• 73

  UprimnyCBayerschmidtSKroissASFritzJNilicaBSvirydenkaHet al. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients With Biochemical Recurrence Referred for (68)Ga-Psma-11 Pet/Ct. J Nucl Med (2021) 62(11):1550–7. doi: 10.2967/jnumed.120.261866

  • CrossRef
  • Google Scholar

• 74

  CornfordPvan den BerghRCNBriersEVan den BroeckTCumberbatchMGDe SantisMet al. Eau-Eanm-Estro-Esur-Siog Guidelines on Prostate Cancer. Part Ii-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol (2021) 79(2):263–82. doi: 10.1016/j.eururo.2020.09.046

  • CrossRef
  • Google Scholar

• 75

  WangYChowDZEbertETajmirSScottJAPalmerEL. Utility of (18)F-Fluciclovine Pet/Ct for Detecting Prostate Cancer Recurrence in Patients With Low (< 1 Ng/Ml) or Very Low (< 0.3 Ng/Ml) Prostate-Specific Antigen Levels. AJR Am J Roentgenol (2020) 215(4):997–1001. doi: 10.2214/ajr.19.22180

  • CrossRef
  • Google Scholar

• 76

  GieselFLFiedlerHStefanovaMSterzingFRiusMKopkaKet al. Psma Pet/Ct With Glu-Urea-Lys-(Ahx)-[(6)(8)Ga(Hbed-Cc)] Versus 3d Ct Volumetric Lymph Node Assessment in Recurrent Prostate Cancer. Eur J Nucl Med Mol Imaging (2015) 42(12):1794–800. doi: 10.1007/s00259-015-3106-6

  • CrossRef
  • Google Scholar

• 77

  RauscherIMaurerTBeerAJGranerFPHallerBWeirichGet al. Value of 68ga-Psma Hbed-Cc Pet for the Assessment of Lymph Node Metastases in Prostate Cancer Patients With Biochemical Recurrence: Comparison With Histopathology After Salvage Lymphadenectomy. J Nucl Med (2016) 57(11):1713–9. doi: 10.2967/jnumed.116.173492

  • CrossRef
  • Google Scholar

• 78

  KroenkeMSchweigerLHornTHallerBSchwambornKWurzerAet al. Validation of (18)F-Rhpsma-7 and (18)F-Rhpsma-7.3 Pet Imaging Results With Histopathology From Salvage Surgery in Patients With Biochemical Recurrence of Prostate Cancer. J Nucl Med (2022). doi: 10.2967/jnumed.121.263707

  • CrossRef
  • Google Scholar

• 79

  MaurerTGschwendJERauscherISouvatzoglouMHallerBWeirichGet al. Diagnostic Efficacy of (68)Gallium-Psma Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients With Intermediate to High Risk Prostate Cancer. J Urol (2016) 195(5):1436–43. doi: 10.1016/j.juro.2015.12.025

  • CrossRef
  • Google Scholar

• 80

  MaurerTEiberMSchwaigerMGschwendJE. Current Use of Psma-Pet in Prostate Cancer Management. Nat Rev Urol (2016) 13(4):226–35. doi: 10.1038/nrurol.2016.26

  • CrossRef
  • Google Scholar

• 81

  SpruteKKramerVKoerberSAMenesesMFernandezRSoza-RiedCet al. Diagnostic Accuracy of (18)F-Psma-1007 Pet/Ct Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J Nucl Med (2021) 62(2):208–13. doi: 10.2967/jnumed.120.246363

  • CrossRef
  • Google Scholar

• 82

  MingelsCBohnKPRomingerAAfshar-OromiehAAlbertsI. Diagnostic Accuracy of [(18)F]Psma-1007 Pet/Ct in Biochemical Recurrence of Prostate Cancer. Eur J Nucl Med Mol Imaging (2022) 49:2436–44. doi: 10.1007/s00259-022-05693-0

  • CrossRef
  • Google Scholar

• 83

  ZhouJGouZWuRYuanYYuGZhaoY. Comparison of Psma-Pet/Ct, Choline-Pet/Ct, Naf-Pet/Ct, Mri, and Bone Scintigraphy in the Diagnosis of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. Skeletal Radiol (2019) 48(12):1915–24. doi: 10.1007/s00256-019-03230-z

  • CrossRef
  • Google Scholar

• 84

  EpsteinJIEgevadLAminMBDelahuntBSrigleyJRHumphreyPA. The 2014 International Society of Urological Pathology (Isup) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol (2016) 40(2):244–52. doi: 10.1097/pas.0000000000000530

  • CrossRef
  • Google Scholar

• 85

  YakarDNoordzijWKweeTC. Potential Causes of False-Negative Interpretations in 68ga-Psma Pet/Ct for the Detection of Local and Recurrent Prostate Cancer: An Underexposed Issue. Clin Nucl Med (2019) 45(1):e32-5. doi: 10.1097/rlu.0000000000002750

  • CrossRef
  • Google Scholar

• 86

  PrasadVSteffenIGDiederichsGMakowskiMRWustPBrennerW. Biodistribution of [(68)Ga]Psma-Hbed-Cc in Patients With Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Mol Imaging Biol MIB (2016) 18(3):428–36. doi: 10.1007/s11307-016-0945-x

  • CrossRef
  • Google Scholar

• 87

  RistauBTO’KeefeDSBacichDJ. The Prostate-Specific Membrane Antigen: Lessons and Current Clinical Implications From 20 Years of Research. Urol Oncol (2014) 32(3):272–9. doi: 10.1016/j.urolonc.2013.09.003

  • CrossRef
  • Google Scholar

• 88

  PerryETalwarASharmaSO’ConnorDWongLMTaubmanKet al. Non-Prostate Cancer Tumours: Incidence on (18)F-Dcfpyl Psma Pet/Ct and Uptake Characteristics in 1445 Patients. Eur J Nucl Med Mol Imaging (2022). doi: 10.1007/s00259-022-05721-z

  • CrossRef
  • Google Scholar

• 89

  Afshar-OromiehAMalcherAEderMEisenhutMLinhartHGHadaschikBAet al. Pet Imaging With a [68ga]Gallium-Labelled Psma Ligand for the Diagnosis of Prostate Cancer: Biodistribution in Humans and First Evaluation of Tumour Lesions. Eur J Nucl Med Mol Imaging (2013) 40(4):486–95. doi: 10.1007/s00259-012-2298-2

  • CrossRef
  • Google Scholar

• 90

  PfobCHZieglerSGranerFPKohnerMSchachoffSBlechertBet al. Biodistribution and Radiation Dosimetry of (68)Ga-Psma Hbed Cc-a Psma Specific Probe for Pet Imaging of Prostate Cancer. Eur J Nucl Med Mol Imaging (2016) 43(11):1962–70. doi: 10.1007/s00259-016-3424-3

  • CrossRef
  • Google Scholar

• 91

  Afshar-OromiehAHetzheimHKublerWKratochwilCGieselFLHopeTAet al. Radiation Dosimetry of (68)Ga-Psma-11 (Hbed-Cc) and Preliminary Evaluation of Optimal Imaging Timing. Eur J Nucl Med Mol Imaging (2016) 43(9):1611–20. doi: 10.1007/s00259-016-3419-0

  • CrossRef
  • Google Scholar

• 92

  KrohnTVerburgFAPufeTNeuhuberWVoggAHeinzelAet al. [(68)Ga]Psma-Hbed Uptake Mimicking Lymph Node Metastasis in Coeliac Ganglia: An Important Pitfall in Clinical Practice. Eur J Nucl Med Mol Imaging (2015) 42(2):210–4. doi: 10.1007/s00259-014-2915-3

  • CrossRef
  • Google Scholar

• 93

  KinoshitaYKuratsukuriKLandasSImaidaKRovitoPMJr.WangCYet al. Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues. World J Surg (2006) 30(4):628–36. doi: 10.1007/s00268-005-0544-5

  • CrossRef
  • Google Scholar

• 94

  GordonIOTretiakovaMSNoffsingerAEHartJReuterVEAl-AhmadieHA. Prostate-Specific Membrane Antigen Expression in Regeneration and Repair. Mod Pathol Off J United States Can Acad Pathol Inc (2008) 21(12):1421–7. doi: 10.1038/modpathol.2008.143

  • CrossRef
  • Google Scholar

• 95

  ArdiesPJGykierePGoethalsLDe MeyJDe GeeterFEveraertH. Psma Uptake in Mediastinal Sarcoidosis. Clin Nucl Med (2017) 42(4):303–5. doi: 10.1097/rlu.0000000000001543

  • CrossRef
  • Google Scholar

• 96

  FroehnerMTomaMZophelKNovotnyVLaniadoMWirthMP. Psma-Pet/Ct-Positive Paget Disease in a Patient With Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. Case Rep Urol (2017) 2017:1654231. doi: 10.1155/2017/1654231

  • CrossRef
  • Google Scholar

• 97

  GykierePGoethalsLEveraertH. Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68ga-Psma Pet/Ct. Clin Nucl Med (2016) 41(7):e346–7. doi: 10.1097/rlu.0000000000001222

  • CrossRef
  • Google Scholar

• 98

  VamadevanSLeKBuiCMansbergR. Incidental Psma Uptake in an Undisplaced Fracture of a Vertebral Body. Clin Nucl Med (2017) 42(6):465–6. doi: 10.1097/rlu.0000000000001599

  • CrossRef
  • Google Scholar

• 99

  ArtigasCOtteFXLemortMvan VelthovenRFlamenP. Vertebral Hemangioma Mimicking Bone Metastasis in 68ga-Psma Ligand Pet/Ct. Clin Nucl Med (2017) 42(5):368–70. doi: 10.1097/rlu.0000000000001631

  • CrossRef
  • Google Scholar

• 100

  KanthanGLIzardMAEmmettLHsiaoESchembriGP. Schwannoma Showing Avid Uptake on 68ga-Psma-Hbed-Cc Pet/Ct. Clin Nucl Med (2016) 41(9):703–4. doi: 10.1097/rlu.0000000000001281

  • CrossRef
  • Google Scholar

• 101

  DerlinTKreipeHHSchumacherUSoudahB. Psma Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68ga-Psma Ligand Pet/Ct. Clin Nucl Med (2017) 42(3):e173–e4. doi: 10.1097/rlu.0000000000001487

  • CrossRef
  • Google Scholar

• 102

  RoweSPGorinMAHammersHJSom JavadiMHawasliHSzaboZet al. Imaging of Metastatic Clear Cell Renal Cell Carcinoma With Psma-Targeted (1)(8)F-Dcfpyl Pet/Ct. Ann Nucl Med (2015) 29(10):877–82. doi: 10.1007/s12149-015-1017-z

  • CrossRef
  • Google Scholar

• 103

  RheeHBlazakJThamCMNgKLShepherdBLawsonMet al. Pilot Study: Use of Gallium-68 Psma Pet for Detection of Metastatic Lesions in Patients With Renal Tumour. EJNMMI Res (2016) 6(1):76. doi: 10.1186/s13550-016-0231-6

  • CrossRef
  • Google Scholar

• 104

  PerezPMFlavellRRKelleyRKUmetsuSBehrSC. Heterogeneous Uptake of 18f-Fdg and 68ga-Psma-11 in Hepatocellular Carcinoma. Clin Nucl Med (2019) 44(3):e133–e5. doi: 10.1097/rlu.0000000000002452

  • CrossRef
  • Google Scholar

• 105

  RolandADrouetCBoulahdourHCochetADe BariB. Unusual Uptakes on (18)F-Fluorocholine Positron Emission Tomography/Computed Tomography (Pet/Ct): A Retrospective Study of 368 Prostate Cancer Patients Referred for a Biochemical Recurrence or an Initial Staging. Quant Imaging Med Surg (2021) 11(1):172–82. doi: 10.21037/qims-19-981

  • CrossRef
  • Google Scholar